DDrare: Database of Drug Development for Rare Diseases

25. 進行性多巣性白質脳症
［臨床試験数：23，薬物数：33（DrugBank：20），標的遺伝子数：7，標的パスウェイ数：36］

Searched query = "Progressive multifocal leukoencephalopathy", "PML", "Leukoencephalopathy, progressive multifocal"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 111JC101; CYT107; Cidofovir; Collection of blood and urine; Cytarabine; Diagnostic Test: Brain MRI; Didanosine; Emtricitabine; Enfuvirtide; Filgrastim; Interferon alfa; Interferon alfa-2b; Interleukin-7; Lariam; MEFLOQUINE; METHYLPREDNISOLONE; Mefloquine; Methylprednisolone; Neurological evaluation; PREDNISOLONE; Pembrolizumab; Prednisolone; Probenecid; PyVST; Recombinant human interleukin-7; Spinal tap; Tenofovir; Tenofovir-Emtricitabine; Teriflunomide; Topotecan; Tysabri; Zalcitabine; Zidovudine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00002395 (ClinicalTrials.gov)	June 1996	2/11/1999	Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)	An Open, Comparative Phase II Study of Immediate Versus Delayed Treatment With Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy	HIV Infections;Leukoencephalopathy, Progressive Multifocal	Drug: Topotecan	SmithKline Beecham	NULL	Completed	18 Years	N/A	Both	54	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00002395
(ClinicalTrials.gov)

June 1996

2/11/1999

Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)

An Open, Comparative Phase II Study of Immediate Versus Delayed Treatment With Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy

HIV Infections;Leukoencephalopathy, Progressive Multifocal

Drug: Topotecan

SmithKline Beecham

NULL

Completed

18 Years

N/A

Both

Phase 2

United States